TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05944757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP plasma rich platelets
Description: Twenty patients (20) underwent 0.5 ml 100 % intrastromal injection of PRP plasma rich platelets (first group) every 2 weeks for one month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Autologous serum
Description: Twenty patients (20) underwent intrastromal injection of 0.5 ml 100 %of autologous serum (second group) every 2 weeks for 1 month
Study: NCT06053996

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hepatopulmonary radio-sterilization
Description: Hepatopulmonary radio-sterilization - ablation of hepatic and pulmonary metastases

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hepatopulmonary radio-sterilization
Description: Hepatopulmonary radio-sterilization - ablation of hepatic and pulmonary metastases
Study: NCT05914740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided functional remodeling of lower extremity superficial vein valve
Description: Preoperative ultrasound was used to re-evaluate and confirm the valve function, disinfect the tissue, inject hyaluronic acid around the great saphenous vein valve to reshape the valve about 1-2ml, monitor the whole process under ultrasound, pump back for protection during injection, and inject multiple times at different points.
Study: NCT06043934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilization with Intermittent Cervical Traction
Description: This group will receive Neural Mobilization with Intermittent Cervical Traction along with routine physical therapy. The patient will be positioned in a supine position with 10 to 15 degrees of flexion on a comfortable treatment table. A suitable pillow will be arranged to support their head. The cervical traction device's integrity and readiness will be confirmed by the therapist. The starting weight will be about 10% of the patient's body weight, and this will slowly increase up to an appropriate level. The on-and-off times will be decided based on the patient's comfort and specific condition. Generally, a ratio of 3:1 or 4:1 (hold: rest) is used. For instance, 60 seconds of traction followed by 20 seconds of rest. The total treatment time will generally range between 15-20 minutes for 3 to 4 times per week. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neural Mobilization
Description: This Group will receive Neural Mobilization with routine physical therapy. Each nerve glide exercise will be performed ideally around 2-3 times, depending on the patient's comfort and tolerance levels. The intensity of the exercise is governed by the degree of stretch applied to the nerve. This should be within the patient's comfort level, causing a mild stretching sensation rather than pain. Each nerve glide will be performed in a set of 10-15 repetitions. Rest periods should be provided between each repetition and set, ensuring the patient's comfort.~In median nerve glide the patient will be seated comfortably. Their arm will be guided into shoulder depression, elbow extension, forearm supination, and wrist and finger extension. The patient will then be instructed to slowly flex and extend their wrist while maintaining the other positions. Participants will be scheduled to attend 12 treatment sessions ( 3-4 sessions every week for 4 weeks; 45 min each session).
Study: NCT06034041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mediclore
Description: After finish the operation, Mediclore group will be applied 1.5 CC of Mediclore at the surgical site. Mediclore is a Poloxamer-based thermosensitive anti-adhesive agent which is in a liquid solution and transform to a gel-state after being in a body temperature.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: After finish the operation, Control group will be applied 1.5 CC of normal saline at the surgical site.
Study: NCT04510584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant humanized IgG1 monoclonal antibody that binds VEGF, a secreted factor that stimulates angiogenesis. Bevacizumab prevents the interaction of VEGF with its receptors and neutralizes the biological activity of VEGF.
Study: NCT06791733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive static stretching
Description: the intervention consists of passive static stretching of agonist or antagonist muscles between sets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive static stretching
Description: the intervention consists of passive static stretching of agonist or antagonist muscles between sets
Study: NCT06792110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence Integrated Hearing Aid Use
Description: Participants in this arm will use the study-designed artificial intelligence-integrated hearing aid in the listening tasks. Participants will also perform the listening tasks without hearing aids to act as controls.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence Integrated Hearing Aid Use
Description: Participants in this arm will use the study-designed artificial intelligence-integrated hearing aid in the listening tasks. Participants will also perform the listening tasks without hearing aids to act as controls.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Infineo Hearing Aid
Description: Participants in this arm will use a fitted commercial hearing aid in the listening tasks. Participants will also perform the listening tasks without hearing aids to act as controls.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oticon Real Hearing Aid
Description: Participants in this arm will use a fitted commercial hearing aid in the listening tasks. Participants will also perform the listening tasks without hearing aids to act as controls.
Study: NCT06783946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: The meditation technique will be comprised of breathing techniques, full body relaxation, color meditation, visualization, and positive affirmations. A physician researcher trained in teaching meditation will conduct virtual meditation sessions with patients enrolled in the study. Participants will practice a daily 20-minute meditation for 2-4 weeks before scheduled surgery (whichever is the maximum length of time from enrollment) to 2 weeks post-operatively using the provided audio guided meditation recordings. Participants will also log completion of daily meditation practice electronically.
Study: NCT06790329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic sleeve gastroplasty with fundal mucosal ablation
Description: Mucosal ablation around the gastric fundus is initially performed using a hybrid argon plasma coagulation (H-APC) probe, following a submucosal saline injection, until ablation coagulum is visible. Subsequently, endoscopic sleeve gastroplasty (ESG) is performed using a full-thickness endoscopic suturing device (Overstitch, Apollo). This is done in a standard manner, employing 6-8 permanent full-thickness sutures along the greater curvature of the stomach in a running plication, starting from the angular incisura and extending proximally while sparing the fundus. Hemostasis is carefully checked and confirmed before the procedure is completed.
Study: NCT06791460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin plus adebrelimab with mirabegron
Description: Participants receive pegylated liposomal doxorubicin at a dose of 20mg/m2 plus adebrelimab at a dose of 20 mg/kg via intravenous (IV) infusion plus on Day 1 of each 21-day cycle orally with daily mirabegron until intolerance or disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin plus adebrelimab
Description: Participants receive pegylated liposomal doxorubicin at a dose of 20mg/m2 plus adebrelimab at a dose of 20 mg/kg via intravenous (IV) infusion plus on Day 1 of each 21-day cycle until intolerance or disease progression.
Study: NCT06790862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302Base gel
Description: SHR0302Base gel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302Base gel
Description: SHR0302Base gel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302Base gel
Description: SHR0302Base gel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR0302Base gel placebo
Description: SHR0302Base gel placebo.
Study: NCT06791629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation
Description: Patients will be treated with pulsed field ablation for atrial fibrillation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: Patients will be treated with radiofrequency ablation for atrial fibrillation.
Study: NCT06790563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromodulation
Description: Neuromodulation by UCon
Study: NCT06792058

Intervention type: DEVICE
Intervention: Mechanomiograph: The gold standard of quantitative monitoring
Description: The gold standard of quantitative monitoring is mechanomyography (MMG), which measures the force of contraction of the adductor pollicis muscle following ulnar nerve stimulation. MMG responses are accurate and reproducible. However, the complex and bulky devices are only suitable for research use, are not suitable for clinical use and are not commercially available.

Intervention type: DEVICE
Intervention: Electromiograph
Description: Another type of monitor is the electromyograph, which can be seen as an alternative to mechanomyography because of its accuracy. This technique measures muscle activity as a summation of the action potentials of muscle fibres. This activity is proportional to the strength of the muscle contraction. The most commonly innervated nerve is also the ulnar nerve, which innervates the abductor digiti minimi and the first dorsalis interosseus muscles. During the measurements, electrical signals from these muscles are detected. EMG has several advantages over other monitoring techniques. It does not require immobilisation of the hand, thumb immobility is not a problem, no preload is required, and hypothermia does not affect the hand as much as other neuromuscular monitors. The TetraGraph (Senzime AB, Sweden) is a portable EMG-based neuromuscular minitor for which the manufacturers received marketing approval from the U.S. Food and Drug Administration (FDA) in 2019.
Study: NCT06792149

Intervention type: PROCEDURE
Intervention: surgical resection
Description: Surgical resection will be performed for locoregional lesions .

Intervention type: PROCEDURE
Intervention: surgical resection
Description: Surgical resection will be performed for locoregional lesions .

Intervention type: PROCEDURE
Intervention: surgical resection
Description: Surgical resection will be performed for locoregional lesions .

Intervention type: OTHER
Intervention: Adjuvant chemotherapy
Description: Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.

Intervention type: OTHER
Intervention: Adjuvant chemotherapy
Description: Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.

Intervention type: OTHER
Intervention: neoadjuvant therapy
Description: Regimens of neoadjuvant chemotherapy are directed by clinicalguidance and experience
Study: NCT06791070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin combined with Toripalimab
Description: Disitamab Vedotin at a dosage of 2mg/kg and 3mg/kg of Toripalimab administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
Study: NCT05509400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: DB Phase: Rimegepant 75 mg Orally Disintegrating Tablet (ODT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DB Phase: matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rimegepant
Description: OLE Phase: Rimegepant 75 mg ODT in association with each of the first 5 qualifying migraines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: OLE Phase: Rimegepant 75 mg ODT in association with each of the first 5 qualifying migraines
Study: NCT06791915

Intervention type: PROCEDURE
Intervention: Radiofrequency Ablation with FCV.
Description: Treatment of atrial fibrillation patients with radiofrequency ablation under general anesthesia with Flow Controlled Mechanical Ventilation (FCV).

Intervention type: PROCEDURE
Intervention: Radiofrequency Ablation with VCV.
Description: Treatment of atrial fibrillation patients with radiofrequency ablation under general anesthesia with Volume Controlled Mechanical Ventilation (VCV).
Study: NCT06369285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information.~1 mg of anastrozole tablet by mouth once daily or~2.5 mg of letrozole tablet by mouth once daily or~25 mg of exemestane tablet by mouth once daily or~20 mg of tamoxifen tablet by mouth once daily or~500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information.~1 mg of anastrozole tablet by mouth once daily or~2.5 mg of letrozole tablet by mouth once daily or~25 mg of exemestane tablet by mouth once daily or~20 mg of tamoxifen tablet by mouth once daily or~500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information.~1 mg of anastrozole tablet by mouth once daily or~2.5 mg of letrozole tablet by mouth once daily or~25 mg of exemestane tablet by mouth once daily or~20 mg of tamoxifen tablet by mouth once daily or~500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter
Study: NCT04931407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A 12-week interdisciplinary complex intervention
Description: The intervention will last for 12 weeks and includes four components; patient education, physical exercise, cognitive behavioral program and nutritional counseling.~The patient education will include an online 2-hours group-based patient-education sessions in week 1.~The physical exercise program includes two weekly exercise sessions, one supervised by a physiotherapist and one unsupervised, including aerobic exercise, resistance exercise and psychometric physiotherapy. Half of the intervention group (N=7) will perform the supervised exercise session individually with a physiotherapist in the municipality, while the other half (n=8) will exercise in online groups lead by physiotherapists.~The cognitive behavioral program will begin in week 3 and include six group-based online sessions every week lead by a clinical psychologist.~The nutritional counseling will include three individual digital nutrition counselling sessions in week 2, 6 and 10 by a clinical dietitian.
Study: NCT06201741

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [131I]/[18F]/[68Ga]ZT-111
Description: \[131I\]/\[18F\]/\[68Ga\]ZT-111, single dose
Study: NCT04903704

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 1 Minute Sit to Stand Test
Description: Participants are asked to stand repeatedly from a chair for one minute without the use of their arms for support. The number of completed repetitions is counted.
Study: NCT04705987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: Colchicine 0.5 mg/24h Treatment 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1c/24h Treatment 8 weeks
Study: NCT06792071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radically Open Dialectical Behavior Therapy (RO DBT)
Description: The intervention is a psychological treatment using Radically Open Dialectical Behavior Therapy (RO-DBT), consisting of individual therapy and skills training in group for approximately 22 weeks. Additionally, a parent group consisting of four sessions will be included as an adaptation to the adolescent group.
Study: NCT06791278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After-school childcare educators will participate in a professional development course on delivering pedagogical and child-friendly exercise sessions. The children will receive 1-2 weekly sessions of 45-60 minutes of child-friendly exercise during after-school childcare programs. Duration: 1 year.
Study: NCT06516458

Intervention type: DIAGNOSTIC_TEST
Intervention: Camera Based Kinematic Analysis
Description: Observational Study using Camera Based, Marker Less Kinematic Analysis of gait quality of persons with Multiple Sclerosis
Study: NCT05381207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast Oral Tablet
Description: Subjects in group A (study) will be treated with Fluticasone Furoate nasal: (50 micrograms/spray) 100 micrograms (2 sprays) in each nostril twice daily plus oral montelukast (montelukast 10 mg, once a day) for 3 months. Subjects group B (control) will receive only topical steroids in an identical regimen
Study: NCT06790771

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose Supplement
Description: Participants in this intervention receive approximately 10 grams of the supplement, containing 9,000 mg of L-arginine, 200 mg of resveratrol, 500 mg of tart cherry, and 100 mg of vitamin C. The supplement is consumed in powdered form after an 8-hour fasting period. Following a 60-minute rest, participants eat an ad libitum meal to assess the supplement's effect on hunger and food intake. Blood samples are collected at eight specific time points to measure metabolic markers, including GLP-1 levels, while hunger is tracked using a 7-point satiety scale. This intervention aims to determine the effects of a high dose of the supplement on appetite suppression and metabolic responses.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Dose Supplement
Description: In this intervention, participants consume approximately 5 grams of the supplement, which contains 4,500 mg of L-arginine, 100 mg of resveratrol, 250 mg of tart cherry, and 50 mg of vitamin C. The protocol mirrors that of the high-dose intervention: participants arrive after fasting for 8 hours, consume the supplement, rest for 60 minutes, and eat the standardized ad libitum meal. Blood samples are taken at the same eight time points to assess metabolic responses, and hunger levels are measured using the same satiety scale. This intervention investigates whether a lower dose of the supplement can still significantly affect hunger and GLP-1 secretion.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo intervention involves participants consuming a \~5 g inert powder with no active ingredients. Participants follow the same protocol as the other two interventions, including fasting, baseline blood collection, supplement (placebo) consumption, a 60-minute rest, and an ad libitum meal. Blood samples are collected at eight time points, and hunger levels are assessed with the 7-point scale. This intervention serves as a control, helping to determine whether observed effects in the other two interventions are attributable to the active supplement ingredients.
Study: NCT06791811

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OFA
Description: Prior to the induction of anesthesia the patients in OFA group will receive Dexmedetomidine loading dose 1 μg/kg i.v. infusion, and Lidocaine loading dose 1.5 mg/kg i.v. infusion.~The weight based doses of dexmedetomidine, lidocaine will be prepared in a 20 ml syringe and infused over 10 minutes prior to induction.~Then after induction maintenance drugs will be infused as follow:~Dexmedetomidine 0.25-0.5 μg/kg/h (200 micogram in 50cc syrige with infusion rate 0.125-0.250ml/kg/h), and Lidocaine 2mg/kg/h (400mg in 20cc syringe with infusion rate 0.1 ml/kg/h)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OA
Description: In the opioid anaesthesia group patients will receive fentanyl 2 μg/kg loading dose which will be prepared over 20 ml syringe and infused over 10 minutes prior to induction, Then after induction maintenance of analgesic infusion by fentanyl 0.5-1 μg/kg/h (200 micograms in 50 cc syringe with infusion rate 0.125-0.250ml/kg/h).Placebo (saline infusion) in 20 cc syringe with rate infusion rate 0.1 ml/kg/h.
Study: NCT06790511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bioactive highly filled injectable flowable composite
Description: bioactive highly filled injectable flowable composite

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: highly filled injectable flowable composite
Description: highly filled injectable flowable composite
Study: NCT06790498

Intervention type: BIOLOGICAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: No interventions in this trial